Navigation Links
Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
Date:5/14/2009

ify or obtain rights to new products; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the fiscal quarter ended March 31, 2009 (File No. 001-34186). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
2. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
5. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports First Quarter 2009 Results
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... used in ophthalmology and other medical fields holds potential to reveal how blood ... treatments and reduce stroke-induced damage to the brain. , A new article published ...
(Date:7/6/2015)... Worcester, Mass. (PRWEB) , ... July 06, 2015 ... ... by Worcester Polytechnic Institute (WPI), offers new insights into how virulent fungi adapt ... block their spread, and how that battle leaves them temporarily weakened. These insights ...
(Date:7/6/2015)... (PRWEB) , ... July 06, 2015 , ... ... Personalized Medicine, recently hosted their 2015 bi-annual Pain Management Medical Advisory Board meeting ... with Proove Biosciences’ executive Research and Development team to discuss new clinical practice ...
(Date:7/6/2015)... 2015  Approximately 1% of the population inherits a ... These individuals are three times more likely to develop ... of the nation,s leading medical journals by researchers from ... Photo - http://photos.prnewswire.com/prnh/20150706/230685 ... roseola (also known as "sixth disease") and occasional seizures ...
Breaking Biology Technology:Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 2Reducing Stroke Damage May be Next Application for OCT Technology Now Widely Used in Eye and Vision Healthcare 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 2Inherited Herpes Virus Increases the Risk of Angina Reports HHV-6 Foundation 3
... OTTAWA, May 5 /PRNewswire/ - DNA Genotek, ... stabilization and preparation, today announced that The Anthony Nolan ... selected Oragene DNA for a pilot project aimed at ... as HLA registries, use HLA DNA testing to match ...
... CHICAGO, Illinois , May 5, 2010 ... tuberculosis,(TB) will shortly start phase II clinical trials. The ... vaccine called RUTI(R),in conjunction with an antibiotic. This cuts ... side effects and healthcare costs, by preventing,re-infection during the ...
... UCLA researchers report in the April 30 edition of the ... structure at a resolution high enough to effectively "see" atoms, ... a resolution. The research team, led by ... used cryo-electron microscopy to image the structure at 3.3 angstroms. ...
Cached Biology Technology:DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 2DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 3DNA Genotek's Oragene(R) DNA Product Selected by The Anthony Nolan Trust for Pilot Project 4Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 2Archivel Farma's TB Vaccine May Cut Treatment Time From Nine Months to One 3UCLA researchers use new microscope to 'see' atoms for first time 2UCLA researchers use new microscope to 'see' atoms for first time 3
(Date:6/25/2015)...  TAKE Solutions Ltd., a global business technology solutions ... Patent and Trademark Office (USPTO) for its "Method for ... Clinical Accelerators to reduce the time taken to standardize ... without the accelerators), thus reducing time to market. ... the heart of the patented Clinical Data Standardization Process ...
(Date:6/24/2015)... , June 24, 2015  Synaptics Inc. ... human interface solutions, today announced that Sharp has ... provide secure authentication for its latest flagship smartphone ... more than 200 million shipments of its fingerprint ... reinforces Synaptics, strength, scalability and leadership in the ...
(Date:6/23/2015)... Minn. , June 23, 2015   ... company that supports the entire spectrum of clinical ... iMedNet ™ , the company,s intuitive, ... been awarded a Silver 2015 Stevie® Award by ... Health Products & Services Website category.  The American ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2MedNet Solutions' iMedNet eClinical Wins Silver Stevie Award 2
... animals usually congregate for protection or mating or to capture ... found that the terrestrial hermit crab has a more self-serving ... and move into a larger home., All hermit crabs appropriate ... so species of land-based hermit crabs popular terrarium pets ...
... . U.S. Department of Agriculture (USDA) ... soils with manure also can help restore soils on ... land with little or no vegetation, once mined for ... Missouri, southeastern Kansas, and northeastern Oklahoma. The mining activities ...
... LAKE CITY, Oct. 25, 2012 /PRNewswire-iReach/ -- New research ... in Portland, Maine have demonstrated improvements in health behaviors ... chronic disease and rising health care costs continue to ... to reduce health risks and improve ...
Cached Biology News:Hermit crabs socialize to evict their neighbors 2Hermit crabs socialize to evict their neighbors 3Minimizing mining damage with manure 2New Study Shows That Improvements in Employee Health Behaviors Persist Over Two Years 2
Abgene's ALTO-8 is the first automated decapper/capper for Abgene Twist-Lock tubes....
Sterile, individually wrapped, 4mm Cuvettes...
... III RNase H- Reverse ... improved version of SuperScript™ ... Like SuperScript™ II it ... strand from single-stranded RNA ...
S-100A10 (H-80)...
Biology Products: